Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Astellas’ DNA Vaccine for Peanut Allergy Granted FDA Fast-Track Status
Astellas Pharma said on December 20 that its investigational DNA vaccine ASP0892 was granted fast-track designation by the US FDA for the mitigation of severe hypersensitivity reactions due to peanut allergy. ASP0892, which was licensed from US biotech Immunomic Therapeutics,…
To read the full story
Related Article
- Astellas to Write Off 21.5 Billion Yen as Peanut Allergy Vaccine Fails
June 18, 2021
- Astellas Gains Worldwide Rights to Next-Gen DNA Vaccines
October 13, 2015
- Astellas Licenses Pollinosis Vaccine from Immunomic Therapeutics
February 2, 2015
BUSINESS
- Kissei Discussing Japan Response after EU Panel Recommends Pulling Tavneos Approval
June 29, 2026
- Sanofi Files Venglustat for Gaucher Disease in Japan
June 29, 2026
- Santen’s Myopia Drug Ryjusea Wins Nod in Philippines
June 29, 2026
- Toho Shareholders Approve Trigger for 3D Defense Measures
June 29, 2026
- Nippon Shinyaku Bags Option on Elixirgen’s DMD Candidate
June 29, 2026
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…